1FULTON B, GOA KL. Olanzapine, a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [ J ].Drugs, 1997, 53 (2): 281.
3BYMASTER FP, RASMUSSEN K, CALLIGARO DO, et al. In vitro and vivo biochemistry of olanzapine: a novel, atypical andipsyehotie drug [J ]. Clin Psychiatry, 1997,.58 (Suppl 10): 28.
5ARNT J, SKARSFELDT J. Do novel antipsychotics have similar pharmacological characteristics? Review of the evidence [ J ]. Neuropsychopharmaclogy, 1999, 124:212.
6KAPUR S, ZIPURSKY RB, REMINGTON G, et al. Clinical anti theoretical implications of 5 - HT2 anti D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia [J]. Am J Psychiatry, 1999, 156:286.
7MEI,TZER HY. An overview of the mechanism of action of clozapine [J]. J Clin Psychiatry, 1999, 55 (suppl 13) : 47.
3[1]Meltzer HY, Fibiger HC, Olanzapine: a new typical antipsychotic drug. Neuropsychopharmacology, 1996,14: 83-85.
4[2]Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs, 1997,53 (2): 281-298.
5[3]Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B, 1998,714: 309- 315.
6[4]Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma Utilizing reversed phase highe-performance liquid chromatography with electrochemical detection. J Chromatogr B,1995,658:85-90.
7[5]Bergstrom RF, Callagham JT, Cerimele B J, et al. Pharmacokinetic of olanzapine in elderly and young. Pharm Res, 1995, 12 suppl:s358.
9CENTORRINO F, PRICE BH, TUTTLE M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics [J]. Am J Psychiatry, 2002, 159(1) :109-115.
10HUBL D, KLEINLOGEL H, FROLICH L, et al. Multilead quantitative electroencephalogram profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine[J]. Psychopharmacology, 2001, 158(3) :281-288.
